Abstract Body

RhCMV68-1/SIV vaccines demonstrate a profound ability to protect against SIV challenge, with half of all vaccinated rhesus macaques clearing viremia shortly after infection. A hallmark of RhCMV68-1 vaccines is the induction of CD8 T cells that are non-classically restricted, either by MHC-II or MHC-E molecules. MHC-E restricted cells are necessary for RhCMV68-1 mediated protection, and characterizing these unconventional cells is essential to understand this unique immune response and to improve vaccine efficacy.

We developed novel single-cell methods to isolate and characterize MHC-E restricted CD8 T cells. CD8+ T cells from RhCMV68-1/SIV vaccinated rhesus macaques were stimulated with antigen in vitro (epitopic peptides or autologous SIV-infected CD4+ T cells) and responding cells were isolated on the basis of surface trapped TNF-a and CD69 expression. Next, we performed single cell RNA-seq (scRNA-seq) using the 10x Genomics platform, which enables simultaneous capture of transcriptome data and TCR clonotype from individual cells. As validation, full length TCR alpha/beta pairs were synthesized and used to transduce CD8 T-cells from SIV-naïve macaque, which were used in similar recognition assays.

We characterized MHC-E restricted TCR clonotypic hierarchies from four RhCMV68-1/SIV vaccinated rhesus macaques over more than 2 years. In each animal, a small number of broadly cross-reactive TCRs represents the entire MHC-E restricted response to SIV-infected cells, with a single clone recognizing up to 7 distinct epitopes. TCR alpha/beta transductants replicated the in vivo pattern of antigen recognition. While these TCRs are specific, we further demonstrate the peptide/MHC avidity of these MHC-E restricted clones is significantly lower than conventional MHC-Ia clones.

These data indicate that the broad, MHC-E-restricted epitope recognition is accomplished by a small number of T cell clones using highly cross-reactive TCRs with low functional avidity relative to classical responses. These results provide insight into the mechanisms underlying RhCMV/SIV vector efficacy and demonstrate a novel set of methods that could be used to study any T cell population.